| | |
Corset group
|
No corset group
|
All
|
|---|
| | |
n
|
%
|
n
|
%
|
n
|
%
|
|---|
|
Age (mean, SD)
| |
63.2 (+/− 11.4)
|
62.2 (+/−10.8)
|
62.7 (+/−11.1)
|
|
Gender
|
male
|
236
|
53.4
|
253
|
53.5
|
489
|
53.4
|
| |
female
|
206
|
46.6
|
220
|
46.5
|
426
|
46.6
|
|
KPS
|
<=70
|
204
|
46.2
|
218
|
46.1
|
422
|
46.1
|
| |
>70
|
238
|
53.8
|
255
|
53.9
|
493
|
53.9
|
|
Primary site
|
NSCLC
|
101
|
22.9
|
206
|
43.5
|
425
|
46.5
|
| |
Breast
|
219
|
49.6
|
74
|
15.6
|
175
|
19.1
|
| |
Kidney
|
71
|
16.1
|
88
|
18.6
|
159
|
17.4
|
| |
Melanoma
|
15
|
3.4
|
26
|
5.5
|
41
|
4.5
|
| |
Prostate
|
4
|
0.9
|
13
|
2.8
|
17
|
1.9
|
| |
Other
|
51
|
11.5
|
105
|
22.2
|
98
|
10.6
|
|
Localization
|
Thoracic
|
284
|
64.3
|
279
|
59.0
|
563
|
61.5
|
| |
Lumbar
|
158
|
35.7
|
194
|
41.0
|
352
|
38.5
|
|
Chemotherapy
|
yes
|
242
|
54.7
|
260
|
55.1
|
502
|
54.9
|
| |
no
|
200
|
45.3
|
212
|
44.9
|
412
|
45.1
|
|
Stability before RT
|
stable
|
140
|
31.7
|
320
|
67.7
|
460
|
50.3
|
| |
unstable
|
302
|
68.3
|
153
|
32.3
|
455
|
49.7
|
|
Stability after 3 months
|
stable
|
152
|
39.8
|
279
|
79.0
|
449
|
59.2
|
| |
unstable
|
230
|
60.2
|
79
|
21.0
|
309
|
40.8
|
|
Stability after 6 months
|
stable
|
165
|
45.1
|
311
|
85.2
|
476
|
65.1
|
| |
unstable
|
201
|
54.9
|
54
|
14.8
|
255
|
34.9
|
|
Bisphosphonates
|
yes
|
351
|
79.4
|
296
|
62.6
|
647
|
70.7
|
| |
no
|
91
|
20.6
|
177
|
37.4
|
268
|
29.3
|
|
Distant metastases
|
Brain
|
50
|
11.3
|
77
|
16.3
|
127
|
13.9
|
| |
Lung
|
74
|
16.7
|
118
|
25.0
|
192
|
21.0
|
| |
Liver
|
70
|
15.8
|
116
|
24.5
|
186
|
20.3
|
| |
Skin
|
11
|
2.5
|
25
|
5.3
|
36
|
3.9
|
|
Number of metastases
|
solitary
|
189
|
42.8
|
228
|
48.2
|
417
|
45.6
|
| |
multiple
|
253
|
57.2
|
245
|
51.8
|
498
|
54.4
|
- SD Standard deviation; KPS Karnofsky performance score; RT Radiotherapy
